

Curriculum Vitae: updated February 24, 2026

I. IDENTIFYING DATA

Name Cansu Karakas, MD
Current Position Assistant Professor (University Medical Line), Department of Pathology
Current Affiliation Stanford University
ORCHID ID: 0000-0003-0357-5224

II. EDUCATION HISTORY

Colleges and Universities Attended

2001 MD, Ege University School of Medicine, Izmir, Turkey
2002-2006 Pathology Residency (AP), Celal Bayar University Department of Pathology, Manisa, Turkey

Residency and Fellowship Training

2020 – 2021 Residency (AP/CP), Pathology, Robert Wood Johnson Barnabas Health, Rutgers University, Livingston, NJ
2021 – 2023 Residency (AP), Pathology, University of Rochester Medical Center, Rochester, NY
2023 – 2024 Fellowship, Breast Pathology Brigham and Women’s Hospital, Harvard School of Medicine, Boston, MA

Board Certification

2024 American Board of Pathology (Certification Date 06/23/2023)

Medical License

Medical License: California Medical License, License Number #A 196849 (Active since: 06/11/2024)
Massachusetts Medical License, License Number 1013387 (Active since: 03/29/2024)

III. EMPLOYMENT

Academic Appointments:

8/1/2014 – 7/31/2017 Instructor, University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, Houston, TX

Other Appointments:

10/2007 to 12/2010 Staff Pathologist, Amasya University, Sabuncuoglu Serefeddin Training and Research Hospital, Amasya, Turkey

1/2011 to 7/2014 Visiting Scientist, University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology and Department of Breast Pathology, Houston, TX

08/2014 to 08/2017 Instructor, University of Texas MD Anderson Cancer Center, Department of Experimental Radiation Oncology, Houston, TX

9/2017 to 7/2018 Associate Research Scientist, New York University Langone Health, Department of Pathology

12/2018 to 9/2019 Pathologist, Gelisim Tip Laboratories, Istanbul, Turkey

IV. HONORS AND AWARDS

1999 – 2000 Fourth-Place of the Turkey Professional Basketball League

2004 – 2005 Chief Resident, Department of Pathology, Amasya, Turkey

2023 Honorable Mention, 42nd Biological Stain Commission Conference, Rochester, NY

V. PROFESSIONAL MEMBERSHIPS

2010-Present Member, United States and Canadian Academy of Pathology

2018- Present Member, International Society of Breast Pathology

2024- Present Member, European Society of Pathology

2012- Present Member, Digital Pathology Association

2017- Present Member, American Society of Investigative Pathology

2021-2024 Member, American Society of Molecular Pathology

2010- Present Turkish Pathology Association

2025- Present California Pathology Society

2025- Present Southbay Pathology Society

VI. BIBLIOGRAPHY

Peer-reviewed original research (29 total, 2 submitted, 1 in Preparation)

1. **Karakas C**, Aldrees RA, Mohamed A, Ellis IO, Lester SC et al. Expanded glandular/tubule formation (GTF) for Nottingham grading in invasive breast carcinoma. *Arch Pathol Lab Med*. Published online November 3, 2025. doi: 10.5858/arpa.2025-0280-OA.

2. The added value of an artificial intelligence solution in the identification of microinvasive and T1a carcinomas of the Breast: **First Author**. Status: In preparation (writing) for submission to *Modern Pathology*).
3. Kolhe R, **Karakas C**, Vail E, Deftereos G, Sidiropoulos N. Optimization of Pathologist's roles in molecular biomarker testing in metastatic breast cancer: a consensus statement. Submitted to *Molecular Diagnostics*, January 9, 2026, Status: Under review
4. Simon B, Weiss C, Chan D, **Karakas C**, Curtis L et al. Generative AI enables breast cancer genomic subtype prediction from histology images. Submitted to *Cancer Discovery*, February 3, 2026 (CD-26-0216), Status: Under review
5. Mi L, Lulla A, Wang Y, **Karakas C**, Keyomarsi K. Targeting PKMYT1 in triple-negative breast cancer with low-molecular-weight cyclin E expression. *Cancer Res* 84(22): 3864-88, 2024.
6. **Karakas C**, Love T, Hicks D, Giampoli E, Velez MJ. Validation and interpretation of Pan-TRK Immunohistochemistry: A practical approach and challenges with interpretation. *Diagnostic Pathology* January 10, 2024, doi: 10.1186/s13000-023-01426-5.
7. **Karakas C***, Tyburski H*, Turner B, Weiss A, Medha S et al. HER2 categorical changes after neoadjuvant chemotherapy: A study of 192 matched breast cancers with the inclusion of HER2-Low category. *Histopathol* 142:34-41, 2023.
8. **Karakas C***, Tyburski H*, Finkelman BS, Turney B, Zhang H et al. HER2 mRNA levels better correlate with clinicopathologic features and oncotype DX recurrence scores than HER2 immunohistochemistry in ER positive, HER2 negative breast cancers. *Lab Invest* 104(3):100309, 2023.
9. Lulla A, Akli S, **Karakas C**, Caruso J, Warma L, Keyomarsi K. Neutrophil elastase remodels mammary tumors to facilitate lung metastasis. *Molecular Cancer Therapeutics* October 5th 2023. doi: 10.1158/1535-7163.
10. **Karakas C**, Tyburski H, Turner B, Katerji H, Zhang H. Inter-observer and inter-antibody reproducibility of HER2 immunohistochemical scoring in a HER2-low expressing breast cancer enriched cohort. *American Journal of Clinical Pathology* 159(5): 484-91, 2023.
11. Bagci B, **Karakas C**, Kaur H, Smoller B. Histopathologic features of paraneoplastic granuloma annulare. *Dermatopathology* 10(1): 95-103, 2023.
12. Nguyen TDT, Wang Y, Tuyen BN, Lazcano Segura CN, Ingram DR, Yi M, Pina MA, **Karakas C**. Sequential targeting of Retinoblastoma and DNA synthesis pathways and real time monitoring of response in soft tissue sarcomas. *Cancer Res* 2023;15(83): 939-55.
13. Lulla A, Akli S, **Karakas C**, Ha MJ, Fowlkes N. LMW cyclin E and its catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. *Nature Oncogenesis* 10(5): 40, 2021.
14. Chen X, Yang D, Carey J, **Karakas C**, Albarracin C. Targeting replicative stress and DNA repair by combining PARP and Wee1 kinase inhibitors is synergistic in triple negative breast cancers with cyclin E or BRCA1 alteration. *Cancers* 13(7): 1656, 2021.
15. Johnston S, Syed BM, Parks RM, Monteiro CJ, Caruso JA, Green AR, Ellis IO, Hunt K, **Karakas C**. Cytoplasmic cyclin E is an independent marker of aggressive tumor biology breast cancer-specific mortality in women over 70 years of age. *Cancers* 12(3): 712, 2020.

16. McIntire P, Khan R, Kilic I, Wojcik EM, **Karakas C**. Immunohistochemistry in the workup of bladder biopsies: frequency, variation and utility of use at an academic center. *Ann Diagn Pathol* 41: 124-128, 2019.
17. Chen X, Low KH, Alexander A, Jiang Y, **Karakas C**. Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition. *Clinical Cancer Res* 24(24): 6594-6610, 2018.
18. Carey JP, **Karakas C**, Bui T, Chen X, Vijayaraghavan S. Synthetic lethality of parp inhibitors in combination with myc blockade is independent of BRCA status in triple negative breast cancer. *Cancer Res* 78(3): 742-57, 2018.
19. **Karakas C**, Francis A, Ha MJ, Wingate H, Meena R. Cytoplasmic expression of cyclin E predicts for response to neoadjuvant chemotherapy in breast cancer. *Annals of Surgery* doi: 10.197/SLA3551, 2019.
20. Doostan I, **Karakas C**, Kohansal M, Low KH, Ellis MJ. Cytoplasmic cyclin E mediates resistance to aromatase inhibitors in breast cancer. *Clin Cancer Res* 23(23): 7288-7300, 2017.
21. Vijayaraghan S, **Karakas C**, Doostan I, Chen X, Buyi T. CDK4/6 and autophagy inhibitors synergize to induce senescence in breast cancers with an intact G1/S transition. *Nature Commun* 8: 15916, 2017.
22. Alexander A, **Karakas C**, Chen X, Carey JP, Yi M. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. *Oncotarget* 8(9): 14897-911, 2017.
23. Hunt KK, **Karakas C**, Jin MH, Biernacka A, Yi M. Cytoplasmic cyclin E predicts recurrence in patients with breast cancer. *Clinical Cancer Res* 23(12): 2991-3002, 2017.
24. **Karakas C***, Biernacka A, Bui T, Sahin A, Yi M. Cytoplasmic cyclin E and phospho-CDK2 are biomarkers for aggressive breast cancer. *Am J Pathol* 186(7): 1900-12, 2016.
25. Lucenay KC, Doostan I, **Karakas C**, Bui T, Ding Z. Cyclin E associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. *Cancer Res* 76(8): 2406-18, 2016.
26. Nanos-Webb A, Buyi T, **Karakas C**, Zhang D, Carey JP. PKC δ promotes ovarian tumor progression through deregulation of cyclin E. *Oncogene* 35(19): 2428-40, 2016.
27. Mitri Z, **Karakas C**, Wei C, Brians B, Simmons H. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. *Investigational New Drugs* 45(4): 865-71, 2015.
28. Temiz P, Akkas G, Nese N, Duman F, **Karakas C**. Determination of cell cycle regulators p16, p21, p27, p53, BCL-2, BAX, BCL-XL and cyclin D1 in thyroid follicular carcinoma, follicular adenoma and adenomatous nodules via tissue microarray method. *Turk J of Med Sci* 45(4): 865-71, 2015.
29. Caruso JA, **Karakas C**, Zhang J, Yi M, Albarracin C. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. *Breast Cancer Res* 16(6): 3417, 2014.

Peer-reviewed publications (other - 8 total)

1. **Karakas C**, Nead MA, Velez M. Diffuse pulmonary meningotheliomatosis with Pan-NTRK Immunohistochemical expression: A novel finding and potential pitfall. *Diagnostic Pathol* 18(1):22, 2023.

2. Zhang H, **Karakas C**, Tyburski H, Turner BM, Hicks D. HER2-low breast cancers: Current insights and future directions. *Seminars in Diagnostic Pathology. Semin Diagn Pathol* 39(5): 305-312, 2022.
3. **Karakas C**, Katzman PJ, Wakeman DS, Chacon M. Umbilical appendix masquerading as a patent omphalomesenteric duct in a neonate. *Pediatric and Developmental Pathology.* 25(4):474-478, 2022.
4. Bagci B, **Karakas C**, Gokden M. Subepidermal calcified nodule in a child with neurofibromatosis type-1. *Cureus.* 14(3): e23261, 2022.
5. **Karakas C**, Christensen P, Baek D, Jung M, Ro JY. Dedifferentiated gastrointestinal stromal tumor: recent advances. *Ann Diagn Pathol* 39: 118-124, 2019.
6. **Karakas C**, Wang C, Deng F, Huang H, Wang D. Molecular mechanisms involving prostate cancer racial disparity. *Am J Clin Exp Urol* 5(3): 34-38, 2017.
7. Okus A, Ay S, **Karakas C**, Capraz M, Eryilmaz MA. Liver cyst hydatid fistulated into duodenum. *European Journal of General Medicine* 9(1): 53-55, 2012.
8. **Karakas C**. Paget's disease of the breast. *Journal of Carcinogenesis* 10(1): 100-108, 2011

Non-Peer-reviewed Articles (3)

1. Okus A, **Karakas C**, Capraz A, Capraz M. Primary breast tuberculosis. *Turkiye Klinikleri J Med Sci* 32(3): 809-12, 2012.
2. Yilmaz N, Bereket MC, Gonulol E, **Karakas C**, Temiz P. An uncommon benign tumor of oral minor salivary glands: a case of oncocytoma. *J Dent Fac Ataturk Uni* 4: 77-79, 2011.
3. Okus A, Capraz M, **Karakas C**. Primary splenic flexure volvulus. *National Surgery J* 26(4): 223-224, 2010.

Book Chapters (3 total)

1. **Karakas C**, Sahin A, Resetkova E. Papillary lesions of the breast. In: JP Palazzo, ed. *Difficult Diagnosis in Breast Pathology*. Demos Medical, 2011.
2. **Karakas C**, Sahin A, Resetkova E. Papillary lesions of the breast. In: JP Palazzo, ed. *Surgical Pathology of the Breast Pathology*. Demos Medical, 2018.
3. **Karakas C**, Sahin A. Patient Selection: Breast conserving therapy or mastectomy. In: Kronowitz, ed. *Oncoplastic and Reconstructive Surgery of the Breast*. CRC Press, 2018.

Abstracts (32 total)

1. **Karakas C**, Bean GR, Ernst K, Allison KH, West RB, Troxell ML. Collagenous Myofibroblastic Bundles in Bilateral Breasts of Young Women: When Does Fibrosis Portend Systemic Disease? **Accepted as Poster Presentation**, Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2026, San Antonio TX.

2. **Karakas C**, Etoz S, Good S, Vecsler M, Schnitt S et al. Utilization of an Artificial Intelligence Solution for the Identification of Microinvasive Carcinoma of the Breast. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2024, Baltimore MA.
3. **Karakas C**, Fineberg SA, Lester S, Mohamed A, Aldress R et al. Validation of an expanded description of Glandular (Acinar)/Tubule formation for use in the Nottingham Grading System for invasive breast carcinoma. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2024, Baltimore MA.
4. **Karakas C**, Turney B, Finkelman B, Zhang H, Wang X et al. Negative or low androgen receptor (AR) expression may be associated with higher Ki67 labeling index and Oncotype recurrent score in estrogen receptor (ER) positive invasive breast cancers. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2024, Baltimore MA.
5. **Karakas C**, Bulda M, Loh KP, Aljritawi O, Oltvai Z, Caslet V, Jajosky A. AML relapse after stem cell transplant from a presumed carrier of MyD88 deficiency". Annual Meeting of American Molecular Pathology Europe (AMP), June 2023, Milan, Italy.
6. **Karakas C**, Tyburski H, Liu H, Hicks DG, Zhang H. Dynamic Changes of HER2 Expression in Breast Cancers after Neoadjuvant Chemotherapy with the Inclusion of HER2-low Category. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2023, New Orleans, Louisiana.
7. Tyburski H, **Karakas C**, Zhang H, Liu E, Turner BM, Hicks DG. Correlation of HER2 Immunohistochemical Scores and HER2 mRNA, Oncotype Recurrence Score and Magee Scores on ER Positive, HER2 Negative Breast Cancers. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2023, New Orleans, Louisiana.
8. Tyburski H, **Karakas C**, Liu H, Zhang H, Hicks DG. Streptavidin-coated Phosphor Integrated Dot Fluorescent Nanoparticles (PID) Method could be a more Reliable Method on Detecting Low Levels of HER2 Expression in Breast Cancers. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March, New Orleans, Louisiana.
9. Finkelman BS, Zhang H, Tyburski H, **Karakas C**, Turner BM. Concordance of HER2 IHC Scoring in HER2-Low Breast Biopsy and Subsequent Excision Specimens. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March, New Orleans, Louisiana.
10. **Karakas C**, Huber AR, Agostini-Vulaj D. Clinicopathologic features of benign vascular lesions of the gastrointestinal tract: A single institution experience. Annual Meeting of United States Annual Meeting of United States and Canadian Academy of Pathology (CAP), March 2023, New Orleans, Louisiana.
11. **Karakas C**, Katzman JP, Wakeman DS, Chacon M. Umbilical appendix masquerading as a patent omphalomesenteric duct in a neonate. Society of Pediatric Pathology Virtual Fall Meeting, October 2021.
12. Bagci B, **Karakas C**, Gokden M. Subepidermal calcified nodule (SCN) in a child with Neurofibromatosis type 1 (NF1). American Society of Dermatopathology Virtual Meeting, October 2021.
13. Bagci B, **Karakas C**, Smoller B. Histopathologic features of paraneoplastic granuloma annulare. Society of Pediatric Pathology Virtual Fall Meeting, October 2021.
14. Vijayaraghavan S, **Karakas C**, Chen X, Doostan I, Raghavendra AS. CDK4/6 and autophagy inhibitors synergizes to induce senescence in cancers with an intact G1/S checkpoint. Annual Meeting of American Association of Cancer Research (AACR), April 2017, Washington, WA.

15. Vijayaraghavan S, **Karakas C**, Zhao Y, Wang J, Hunt K, Keyomarsi K. Downregulation of c-myc is synthetic lethal with PARP inhibitors in high myc cancers independent of BRCA status. American Association of Cancer Research (AACR) Precision Medicine Series, January 2017, San Diego, CA.
16. **Karakas C**, Francis A, Yi M, Tucker SL, Sahin A. Cyclin E is a prognostic marker and predictor of response to neoadjuvant chemotherapy and adjuvant hormonal therapy in patients with stage II-III breast cancer. Annual Meeting of American Association for Cancer Research (AACR), April 2015, Philadelphia, PA.
17. Adjapong O, Keyomarsi K, Yi M, **Karakas C**. BRCA1/2 status and low molecular weight cyclin E (LMWE) expression in triple negative breast cancer as a function of race and survival. Annual Meeting of United States and Canadian Academy of Pathology Meeting (USCAP), March 2015, Boston, MA.
18. Mitri Z, **Karakas C**, Briones B, Simmons H, Ibrahim N. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Annual Meeting of American Society of Clinical Oncology (ASCO), September 2014, San Francisco, CA.
19. **Karakas C**, McShane L, Yi M, Trivedi SN, Sahin AA, Hunt K, Keyomarsi K. Assessment of discordances of HER-2 expression and gene amplification: 10% versus 30% cut off? Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2014, San Diego, CA.
20. Alexander A, **Karakas C**, Gong Y, Alvarez R, Ueno NT, Keyomarsi K. Targeting deregulated cyclin E in inflammatory breast cancer via sequential combination therapy. Annual Meeting of San Antonio Breast Cancer Symposium (SABCS), December 2013, San Antonio, TX.
21. **Karakas C**, Biernacka A, Sahin AA, Hunt K, Keyomarsi K. Cytoplasmic staining pattern of cyclin E and pCDK2 expression correlates poor outcome in breast cancer patients. Annual Meeting of United States and Canadian Academy of Pathology (USCAP), March 2012, Vancouver, Canada.
22. **Karakas C**, Graf J, Aleghamand S, Min Y, Leroux J. Clinical significance of staining patterns of cyclin E in breast cancer: a potential use of digital image technology. Annual Meeting of Digital Pathology Association (DPA), October 2012, Baltimore, Maryland.
23. Biernacka A, **Karakas C**, Wingate H, Bondy M, Sahin A. Cytoplasmic cyclin E and PCDK2 expression in triple negative breast carcinoma measured by immunohistochemistry correlates with poor outcome. Annual Meeting of San Antonio Breast Cancer Symposium (SABCS), December 2012, San Antonio, TX.
24. Caruso JA, **Karakas C**, Shen L, Wang J, Albarracin C. Elafin, serine protease inhibitor, is downregulated during breast cancer progression and required for quiescence of human mammary epithelial cells. Annual Meeting of American Association of Clinical Chemistry (AACC), July 2012, Los Angeles, CA.
25. Alexander A, **Karakas C**, Gong Y, Alvarez R, Ueno NT, Keyomarsi K. Can we target the cell cycle? Annual Meeting of Cancer Prevention Institute of Texas (CPIT), August 2012, Austin, TX.
26. **Karakas C**, Gonulol E, Temiz P. Oncocytoma. Presented at the Annual Meeting of International Association of Oral and Maxillofacial Surgery, 2010, Antalya, Turkey.
27. **Karakas C**, Yazar B. Naevoid Melanoma. Presented at the Annual Meeting of National Pathology Congress, 2009, Cyprus.

28. **Karakas C**, Kilic O. Brucella orchitis going to orchiectomy. Presented at the Annual Meeting of National Pathology Congress, 2009, Cyprus.
29. **Karakas C**, Cimen K. Sebaceous carcinoma. Presented at the Annual Meeting of National Pathology Congress, 2009, Cyprus.
30. **Karakas C**, Demir MA, Yuceturk AV. Lymphoepithelioma-like carcinoma of parotid gland. Presented at the Annual Meeting of Cytopathology Congress, 2006, Antalya, Turkey.
31. **Karakas C**, Ayhan S, Saruc M, Kucukmetin N. Intestinal lymphangiectasia. Presented at the Annual Meeting of National Pathology Congress, 2004, Gaziantep, Turkey.
32. Demireli P, **Karakas C**, Celik O, Pabuscu Y. Brown tumor in nasal septum. Presented at the Annual Meeting of National Pathology Congress, 2004, Gaziantep, Turkey.

VII. GRANT FUNDING

Current:

01/2025- Present

Funder: SMART FOUNDATION funding

Title: Early and Late Hormone-positive Ipsilateral Breast Tumor Recurrences' Genomic Signatures

Role: Investigator

08/2025- Present

Funder: Advanced Research Projects Agency for Health (ARPA-H)

Subcontract with University of Washington – SPO# 349

Title: Comprehensive multi-resolution histology of surgical margin surfaces with volumetric co-registration

Role: Co-investigator

VIII. SERVICE TO PROFESSIONAL ORGANIZATIONS (CLINICAL TRIALS & NCI FUNDED COOPERATIVE GROUPS)

Member: NRG Oncology – Breast Cancer Committee (2026- Present)

IX. PATENTS

None

X. EDITORIAL SERVICE

Editor/ Editorial Academy – Modern Pathology (February 1st 2026 – February 1st 2029)

Ad Hoc Reviewer

2014 – 2017

American Journal of Surgical Pathology

2023 – present

Diagnostic Pathology

2017 – present

Breast Cancer Research

2020 – present

Scientific Reports

2023 – present

Molecular Biomedicine

2016 – present

BMC medicine

2025- present

Frontiers in Oncology

XI. SERVICE AS GRANT REVIEWER

None

XII. UNIVERSITY ADMINISTRATIVE SERVICE

None

XIII. SERVICE TO PROFESSIONAL ORGANIZATIONS

None

XIII. INVITED TALKS/PRESENTATIONS (since 2009)

National and Regional Meetings:

1. 2026 “A practical guide to Predictive and Prognostic Biomarkers in Breast Cancer” Short course, Annual Meeting of United States and Canadian Academy of Pathology Meeting (USCAP), San Antonio, TX
2. 2025 “Adenomyoepithelial entities” Invited Talk, Annual meeting of California Society of Pathologists (CSP), Long Beach, LA
3. 2023 “Case based discussion: HER2-low” Invited talk, OncLive State of the Science Summit Breast Cancer Multidisciplinary Meeting, Rochester, NY
4. 2023 “Assessment of Reproducibility of HER2 IHC Scoring in a HER2-low Breast Cancer Enriched Cohort among Breast Subspecialized Pathologists” Platform, Annual Meeting of United States and Canadian Academy of Pathology Meeting (USCAP), New Orleans, Louisiana
5. 2022 “AML relapse after stem cell transplant from a presumed carrier of MyD88 deficiency” Platform, Annual Meeting of Association for Molecular Pathology (AMP), Phoenix, AZ

International Meetings:

6. 2026 “Evolving Concepts in Special Breast Carcinomas and Biomarker Testing: An Integrated Pathology Update”. Invited talk, 36th International Academy of Pathology Congress (IAP2026), Fukuoka, Japan
7. 2013 “Lecture: “Papillary Lesions of the Breast” Invited lecture, National Pathology Symposium”, Izmir, Turkey
8. 2013 “Lecture “Cyclin E and Breast Cancer.” Platform, Early-Stage Breast Cancer and DCIS Symposium, Cappadocia, Turkey
9. 2009 “Significance of Stromelysin 3, Apolipoprotein D and CD34 Immunohistochemical Markers in Diagnosis of Dermatofibroma, Dermatofibrosarcoma Protuberans and Dermatofibrosarcoma Protuberans with Fibrosarcomatous Transformation” Platform, National Pathology Symposium”, Cyprus
10. 2009 “Significance of p53, p16, p21, p27 and Ki-67 Proliferation Index in Pathogenesis of Markers in the Pathogenesis of Dermatofibroma, Dermatofibrosarcoma Protuberans and Dermatofibrosarcoma Protuberans with Fibrosarcomatous Transformation” Platform, National Pathology Symposium”, Cyprus

Grand Rounds:

1. 2023 “The influence of diet and underlying microbial community on anti-tumor immune response”. Intradepartmental Pathology Grand Rounds at University of Rochester Medical Center, Rochester, NY
2. 2022 “Recent Advances in HER2-low Breast Cancers”. Intradepartmental Pathology Grand Rounds at University of Rochester Medical Center, Rochester, NY
3. 2021 “Endometrial Stromal Sarcomas: Molecular advances”. Intradepartmental Pathology Grand Rounds at Saint Barnabas Medical Center, Livingston, NJ
4. 2016 “Cyclin E Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer” Interdepartmental Grand Rounds at MD Anderson Cancer Center, Houston, TX
5. 2013 “The Predictive and Prognostic Role of Cyclin E in Breast Cancer” Interdepartmental Grand Rounds at MD Anderson Cancer Center, Houston, TX

IX. TRAINEES/MENTORSHIP

Elizabeth Ener, MD PhD student, Stanford University

Faculty Mentor, Bio-X fellowship application (submitted), 2026